Melanoma Clinical Trials in Chicago

Showing 141-160 of 284 trials

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

Melanoma, Ocular

Delcath Systems Inc.102 participantsStarted Feb 2016

Tucson, Arizona, United States • Palo Alto, California, United States • Tampa, Florida, United States +21 more locations

COMPLETEDPhase 22.2 miles

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

NCT00071981

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying four different vaccines using melanoma peptides from cytotoxic T cells and helper T cells to see how well they work in treating patients with metastatic melanoma.

Melanoma (Skin)

Eastern Cooperative Oncology Group175 participantsStarted May 2005

Palo Alto, California, United States • Stanford, California, United States • Lewes, Delaware, United States +62 more locations

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma Trials in Other Cities

Safety Study of SEA-CD40 in Cancer Patients

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Chicago